Executive Summary
Leidos Biomedical Research Inc. secured a fully committed $163M NIH NCI contract for health R&D services, with $104M already outlayed, signaling strong revenue visibility through 2028. This cost-plus-fixed-fee 9-year deal underscores predictable cash flows for Leidos Holdings amid sustained federal biomedical investment. Remaining ~$59M outlays present near-term upside, though execution risks over the long horizon warrant monitoring.
Tracking the trend? Catch up on the prior HHS & Healthcare Contracts Intelligence digest from February 20, 2026.
Investment Signals(1)
- Full $163M commitment on 9-year NIH R&D contract(HIGH)▲
$104M outlayed to date with ~$59M remaining provides predictable revenue through 2028-09-29 under cost-plus-fixed-fee structure.
Risk Flags(1)
- Execution[MEDIUM RISK]▼
9-year performance period to 2028-09-29 exposes long-term delivery risks; dependency on $13M across 12 subawards for execution.
Opportunities(2)
- ◆
~$59M remaining outlays on committed $163M contract bolster near-term revenue.
- ◆
Entrenched positioning in NIH NCI health R&D through 2028 positions for follow-on awards.
Sector Themes(1)
- ◆
Full commitment on $163M delivery order highlights stable, long-term federal support for health R&D (PSC AN12) via full-and-open competition.
Watch List(1)
- 👁
{"entity"=>"Leidos Holdings Inc.", "reason"=>"Dominates single-record period with $163M fully committed NIH contract and $59M runway.", "trigger"=>"Outlay acceleration beyond $104M or subaward disruptions"}
Get daily alerts with 1 investment signals, 1 risk alerts, 2 opportunities and full AI analysis of all 1 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC